Pharma BD Deal Intelligence
A $191.7M Inhale-Shearwater pairing that became the PEGylation platform undergirding what Inhale, renamed Nektar Therapeutics in 2003, built its identity on—funding two decades of partnered blockbusters like Neulasta and Pegasys, though the platform was eventually broken up and sold off, culminating in the 2024 Huntsville sale for $90M.
Shearwater's PEGylation platform became the backbone of Nektar's identity and funded two decades of partnered blockbusters, but the asset was eventually sold off piecemeal for a fraction of the value it helped create.
Full analysis, sources & comparables →The addition of this advanced PEGylation technology extends Inhale's portfolio of technologies and significantly expands Inhale's early and late stage human…
Completed the transaction on June 29, 2001... 'With the addition of Shearwater's advanced PEGylation technology platform, Inhale now can provide innovative,…
Pfizer's Somavert (pegvisomant), a PEGylated growth hormone receptor antagonist for acromegaly, validates the long-term commercial value of the Shearwater PEG…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
$72.5M cash + 4M shares ($119.2M); ~$191.7M total. PEGylation reagent platform; later spun into Nektar's PEG business. Sources show range $164M-$191.7M.
Shearwater's PEGylation platform became the backbone of Nektar's identity and funded two decades of partnered blockbusters, but the asset was eventually sold off piecemeal for a fraction of the value it helped create.
Assessment window: 15yr post-close.
PEGylation is a drug-delivery technology that covalently attaches polyethylene glycol (PEG) chains to therapeutic peptides, proteins, antibodies, and small molecules to extend circulation half-life, reduce immunogenicity, and improve solubility. It enables less frequent dosing for biologic drugs and is foundational to multiple multi-billion-dollar marketed products.
In 2001, PEGylation was already the most commercially validated bioconjugation chemistry in the industry, anchoring approved products including Schering-Plough's PEG-Intron (peginterferon alfa-2b) and Roche's Pegasys (peginterferon alfa-2a) for hepatitis C, and Enzon's Oncaspar (pegaspargase) and Adagen (pegademase). Shearwater Corporation, headquartered in Huntsville, Alabama, was the dominant supplier of activated PEG reagents and held the leading IP estate for site-specific PEG chemistry; the Inhale acquisition added 13 partnered programs (11 in clinical testing, 2 already approved) to Inhale's pipeline. Inhale paid $72.5M cash + 4M shares (~$191M total) and the market reacted positively, sending Inhale shares up 5.6% on announcement. Strategically the Shearwater deal — combined with the Bradford Particle Design acquisition five months earlier — gave Inhale a platform spanning particle engineering, molecule engineering, and pulmonary delivery, and set the stage for the January 2003 rebrand to Nektar Therapeutics. The PEG franchise outlasted the inhalable insulin program: it underpins Pfizer's Somavert and Amgen's Neulasta and remains a core Nektar revenue stream.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inhale Therapeutic Systems Inc. / Shearwater Corporation (this deal) | 2001 | $192M | 73 |
| Inhale Therapeutic Systems Inc. / Bradford Particle Design plc (UK) | 2001 | $200M | 14 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals